



## Vanda Pharmaceuticals Announces Presentations at DDW 2022

May 19, 2022

WASHINGTON, May 19, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at Digestive Disease Week (DDW) 2022, to be held in San Diego, CA and online from May 21-24, 2022.

The following will be presented:

### May 21, 2022

Presentation Title: "THE ROLE OF M1 TO M2 MACROPHAGE POLARIZATION IN THE ETIOLOGY OF IDIOPATHIC GASTROPARESIS: GWAS PERSPECTIVE"

Abstract Number: 3752409

Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics

Session Type: Plenary Session

Session Title: Late-Breaking Basic Science Abstract Plenary

Session Time: 2:00 PM to 3:30 PM PDT

Presentation Time: 2:15 PM to 2:30 PM PDT

### May 23, 2022

Presentation Title: "ENRICHMENT OF PATIENTS WITH EHLERS DANLOS SYNDROME IN IDIOPATHIC GASTROPARESIS – A GENE SET ENRICHMENT ANALYSIS"

Abstract Number: 3696881

Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics

Session Type: Poster Session

Session Title: Cell Biology, Biochemistry and Integrative Physiology

Session Time: 12:30 PM to 1:30 PM PDT

For more information on DDW 2022, please refer to <https://ddw.org/>.

### About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit [www.vandapharma.com](http://www.vandapharma.com) and follow us on Twitter @vandapharma.

### Corporate Contact:

Kevin Moran

Senior Vice President, Chief Financial Officer and Treasurer

Vanda Pharmaceuticals Inc.

202-734-3400

[pr@vandapharma.com](mailto:pr@vandapharma.com)

Elizabeth Van Every

Head of Corporate Affairs

Vanda Pharmaceuticals Inc.

202-734-3400

[pr@vandapharma.com](mailto:pr@vandapharma.com)

 View original content: <https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-presentations-at-ddw-2022-301551750.html>

SOURCE Vanda Pharmaceuticals Inc.